- Home
- IMAB vs IOBT Comparison
IMAB vs IOBT Comparison
Compare IMAB & IOBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMAB
- IOBT
- Stock Information
- Founded
- IMAB 2014
- IOBT 2014
- Country
- IMAB United States
- IOBT Denmark
- Employees
- IMAB N/A
- IOBT N/A
- Industry
- IMAB Biotechnology: Pharmaceutical Preparations
- IOBT Biotechnology: Pharmaceutical Preparations
- Sector
- IMAB Health Care
- IOBT Health Care
- Exchange
- IMAB Nasdaq
- IOBT Nasdaq
- Market Cap
- IMAB 83.8M
- IOBT 77.7M
- IPO Year
- IMAB 2020
- IOBT 2021
- Fundamental
- Price
- IMAB $1.39
- IOBT $1.15
- Analyst Decision
- IMAB Strong Buy
- IOBT Strong Buy
- Analyst Count
- IMAB 3
- IOBT 3
- Target Price
- IMAB $8.00
- IOBT $9.33
- AVG Volume (30 Days)
- IMAB 378.4K
- IOBT 901.4K
- Earning Date
- IMAB 08-28-2024
- IOBT 11-11-2024
- Dividend Yield
- IMAB N/A
- IOBT N/A
- EPS Growth
- IMAB N/A
- IOBT N/A
- EPS
- IMAB N/A
- IOBT N/A
- Revenue
- IMAB $3,492,091.00
- IOBT N/A
- Revenue This Year
- IMAB N/A
- IOBT N/A
- Revenue Next Year
- IMAB N/A
- IOBT N/A
- P/E Ratio
- IMAB N/A
- IOBT N/A
- Revenue Growth
- IMAB N/A
- IOBT N/A
- 52 Week Low
- IMAB $0.99
- IOBT $0.73
- 52 Week High
- IMAB $2.54
- IOBT $2.10
- Technical
- Relative Strength Index (RSI)
- IMAB 63.28
- IOBT 53.08
- Support Level
- IMAB $1.02
- IOBT $1.01
- Resistance Level
- IMAB $1.50
- IOBT $1.12
- Average True Range (ATR)
- IMAB 0.10
- IOBT 0.14
- MACD
- IMAB 0.04
- IOBT 0.02
- Stochastic Oscillator
- IMAB 77.08
- IOBT 58.59
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).
About IOBT IO Biotech Inc.
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.